In summary, our findings support a combinatorial strategy integrating targeting of the PRELID1-VDAC3-IL-7 axis in senescence-like Bgc cells with anti-PD-L1 immunotherapy for colorectal cancer. This evidence concerns the gene PRELID1 and colorectal cancer.